FB-HRS, LLC Announces US FDA Clearance of IND Application to Initiate Clinical Trial for FBHRS001, a Treatment for Atrial Fibrillation
Atrial Fibrillation impacts a tremendous amount of people around the world and current treatment options are underwhelming due to negative side effects. FB–HRS, LLC has developed a treatment that may reduce those undesired consequences and successfully treat the condition. The next step is a clinical trial, in which the treatment's viability will be assessed.
Frontida BioPharm and Oncoceutics Announce Product Development and Commercialization Partnership
Frontida BioPharm, Inc. and Oncoceutics Inc. announced that the two companies have entered into a product development and commercialization agreement to further develop and scale-up the finished product manufacturing process for ONC201, Oncoceutics’ lead molecule.
AdaptDose™, The innovation in drug development, that reduces development time by up to 30%
Frontida’s AdaptDose™ technology platform provides a tool that can eliminate the need to reformulate after Phase I and overcomes several technical hurdles in the development and scale up of (1) new molecules, (2) binary and tertiary mixtures of active ingredients, zero and first order drug release matrices, or (3) scalable clinical trial materials used in dose ranging or adaptive dose clinical studies.